Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 05/08/12 -- TriMarkPublications.com cites in its newly published "Game Changers in " report that increased mammograms are up to 65% responsible for reductions in breast cancer mortality. For more information, visit: .
can be categorized into seven main modalities: hormone therapy, surgery, radiation, molecular targeted therapy, chemotherapy, hormone treatment and targeted drug therapy. Every year, 1.3 million women are diagnosed with breast cancer, with over 230,000 new breast cancer diagnoses in the U.S. in 2011. Increased usage of breast cancer screenings in the U.S., the European Union (E.U.) and developing nations has significantly improved recent success rates by identifying the cancer at its earliest and most vulnerable stages.
The "Game Changers in " report covers:
Tumorigenesis
Her2 Positive Breast Carcinoma (Her2+ BC)
Herceptin
Triple Negative Breast Cancer (TNBC)
Applied Biomarkers
Companion Diagnostics
PI3K/mTOR Pathway
Vascular Endothelial Growth Factor (VEGF) Modulators
The "Game Changers in " report examines current and upcoming drugs in the market. Drugs covered include: Abiraterone acetate (Zytiga), Afatinib (Tomtovok), Afimoxifene (TamoGel), Albumin-bound paclitaxel (Abraxane), Anastrozole (Arimidex), Apatinib, Bevacizumab (Avastin), Bosutinib, Capecitabine (Xeloda), Cediranib, Cetuximab (Erbitux), Cixutumumab, Dasatinib (Sprycel), Docetaxel (Taxotere), Dovitinib, Doxorubicin liposomal (Doxil), Eribulin (Halaven), Erlotinib (Tarceva), Everolimus (Afinitor), Exemestane (Aromasin), Fadrozole (Afema), Fluoxymesterone, Fulvestrant (Faslodex), Ganitumab, Gemcitabine (Gemzar), Goserelin (Zoladex), Herceptin SC, Icrucumab, IMP 321, Indibulin, Iniparib, Irinotecan (Campotsar), Ixabepilone (Ixempra), KW 2450, Lapatinib (Tykerb), Letrozole (Femara), Leuprorelin depot (Carcinil), Litronesib, Lobaplatin, MEDI 573, MetMAb, Mitoxantrone (Novantrone), Motesanib, MVA-BN-HER2 AutoVac, N-Acetyl GM3 vaccine, N-Glycolyl GM3 cancer vaccine, Neratinib, Oblimersen (Genasense), Orantinib, Oxaliplatin (Eloxatin), Pazopanib (Votrient), Pemetrexed (Alimta), Pertuzumab (Omnitarg), Pixantrone, Pralatrexate (Folotyn), Raloxifene (Evista), Ramucirumab, Ridaforolimus (MK-8669), Sorafenib (Nexavar), Trastuzumab (Herceptin), Trastuzumab biosimilar, Trastuzumab emtansine (T-DM1), Trilostane, Triptorelin, TVAX cancer vaccine, Varlitinib, Veliparib, Vinflunine, Vinorelbine (Navelbine), Vorinostat (Zolinza) and Zibotentan.
For more information, visit: .
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit .
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
TriMarkPublications.com
Media Relations
1-888-OK-TRIMARK
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.05.2012 - 17:45 Uhr
Sprache: Deutsch
News-ID 144070
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 263 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction"
steht unter der journalistisch-redaktionellen Verantwortung von
TriMarkPublications.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
